Health

Accelerating access to modern medical care

Tackling some of the most pressing healthcare challenges facing our societies today must be one of our biggest priorities.

We are focused on accelerating access to modern medical care for those who need it most, while addressing unmet medical needs in developing markets around the world.

We believe that access to health should be a basic human right.

An individual’s birthplace, proximity to infrastructure, or lack of wealth should not deny that access; and yet for many communities, that is the everyday reality.

The Jameel family’s commercial and non-commercial interests in the health sector reflect this ethos of inclusivity.

"Improving access to healthcare is a complex puzzle requiring deep understanding of both needs and solutions – including technology, infrastructure, and distribution.

"Addressing these issues has proved to be one of society’s biggest challenges.

"But now more than ever, we have the technology and expertise to start making real progress. And I’m hugely excited by the opportunities ahead."

Fady Jameel
Vice Chairman, International
Abdul Latif Jameel

Rare Disease and Specialist Therapeutics

International:

In 2024, Abdul Latif Jameel acquired a strategic stake in the internationally successful UAE-based specialty pharmaceutical business, Genpharm. This led to the full acquisition of Genpharm in 2025.

Founded in 2012, today, Genpharm operates in over 13 markets with a core strength centered on niche therapeutics for rare diseases.

This focus has a particular emphasis on neuromuscular, lysosomal storage disease and ophthalmology, dermatology, and more. Genpharm’s portfolio also encompasses leading therapies for women’s health and specialty care as well as central nervous system disorders.

Genpharm is also the first to bring gene therapy to the Middle East region. By partnering with biotechnology leaders and pioneers in the field, this has accelerated access to innovative cures and treatments to patients across MENA.

Rehabilitation

Saudi Arabia:

Inaugurated in 1997, and covering 43,000m2, including eight wards with 120 beds and extensive gardens, the Abdul Latif Jameel Hospital was first healthcare facility of its kind pioneering medical rehabilitation in Saudi Arabia.

The Abdul Latif Jameel Hospital has helped over 95,000 patients and offers comprehensive and distinctive rehabilitation programs for adults and children including intensive day-care, recreational therapy programs for the inpatients, an autism care program, outpatient treatment, medical services, and home care.

Harnessing innovative technologies in healthcare space, the Abdul Latif Jameel Hospital became a pioneer in the use of Cyberdyne robotic exoskeletons for the treatment of spinal injury.  An initiative which has led to us being the distributor for the GCC region and a regional training center.  In 2025, the Abdul Latif Jameel Hospital celebrated its 30th anniversary.

Philanthropy & Advanced Research

International:

The Jameel family’s long-established philanthropy, Community Jameel, and its focus on furthering science to help communities thrive in a rapidly changing world, also encompasses advancing the future of health.

In 2018, Community Jameel co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) at MIT, and in 2019, the Abdul Latif Jameel institute for Disease & Emergency Analytics (Jameel Institute) at Imperial College London.

The Jameel Institute brings together researchers from multiple disciplines to utilize expertise in data analytics to help combat disease threats worldwide.


The Institute improves our understanding of disease across populations linking governments, research institutions, and communities, to develop effective long-term solutions, shape health policy and ultimately, deliver a better quality of life.


The Institute has three main research themes: responding to health emergencies, strengthening health systems, and building partnerships and capacity.

2018

Jameel Clinic at MIT

2019

Jameel Institute at Imperial College

The MIT Jameel Clinic drives the creation of high-precision, affordable and scalable AI technologies to revolutionize healthcare across the key areas: clinical AI, drug discovery and epidemiology.


It is working on novel algorithms for modelling biological and clinical data, while striving toward new discoveries in machine learning, biology, chemistry and clinical sciences.  This research led to significant breakthroughs including new antibiotics halicin and abaucin, and clinical AI tools, such as MIRAI and SYBIL.

Our Businesses

Health Health
Transportation Transportation
Engineering and Manufacturing Engineering and Manufacturing
Financial Services Financial Services
Land and Real Estate Land and Real Estate
Energy and Environmental Services Energy and Environmental Services
Consumer Products Consumer Products
Advertising and Media Advertising and Media